LEGN Legend Biotech USA Inc.
Price Chart
Executive Summary
Legend Biotech announced promising Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, showing 100% ORR and 83.3% CR at dose level 2 in relapsed/refractory B-NHL, with no DLTs or SAEs. The data will be presented at EHA 2026 (June 11-14), providing a near-term catalyst. This is an early-stage, small-sample (n=12) readout, but the novel off-the-shelf approach could expand CAR-T access if confirmed in larger trials.
Actionable Insight
The EHA 2026 presentation on June 14 is the key catalyst — watch for additional efficacy durability and safety details. The small sample (n=12) and short follow-up limit conviction; a larger Phase 2/3 trial is needed to confirm. For now, this is a positive early signal for Legend's pipeline beyond CARVYKTI.
Key Facts
- Phase 1 data for LB2501 (in vivo CAR-T) shows 100% ORR (6/6) and 83.3% CR (5/6) at dose level 2 in R/R B-NHL
- No DLTs, SAEs, ICANS, or Grade ≥3 CRS observed; all CRS ≤ Grade 2
- CAR-T cells detected in peripheral blood for up to 116 days without lymphodepletion
- Data to be presented at EHA 2026 late-breaking session on June 14, 2026
- LB2501 is built on the proprietary TaVec lentiviral vector platform
- Median follow-up at DL2 was only 2.2 months (range 2.0–3.8); durability is early
Financial Impact
No financial data provided; early-stage pipeline readout with no revenue impact. Potential market expansion for in vivo CAR-T if successful.
Risk Factors
- Very early-stage data (n=12, median follow-up 2.2 months) — durability and larger-sample results unknown
- In vivo CAR-T is a novel modality with unproven long-term safety and manufacturing scalability
- Competition from other in vivo CAR-T approaches (e.g., Capstan, Sana) and approved CAR-T products
- No financial or regulatory milestones provided; clinical risk remains high
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305321 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
4d ago
|
6-K
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $32.62 (−10.09%) |
|
Jun 2, 2026
4d ago
|
Press Release
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $32.62 (−10.09%) |
|
Jun 1, 2026
5d ago
|
6-K
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $32.62 (+27.87%) |
|
Jun 1, 2026
5d ago
|
Press Release
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $32.62 (+27.87%) |
|
May 21, 2026
16d ago
|
6-K
| — | awaiting T+1 | — | — |
|
May 21, 2026
16d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 12, 2026
25d ago
|
6-K
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $32.62 (+15.43%) |
|
May 12, 2026
25d ago
|
Press Release
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $32.62 (+15.43%) |
|
Apr 28, 2026
5w ago
|
Press Release
| $23.56 $22.77 | ▼ −3.35% | ▼ −3.34% | $32.62 (+38.46%) |
|
Apr 14, 2026
7w ago
|
6-K
| $18.69 $20.52 | ▲ +9.79% | ▲ +9.02% | $32.62 (+74.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access